Overview

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.

Phase:

Phase 2

Details

Lead Sponsor:

Avanir Pharmaceuticals

Treatments:

Antidepressive Agents
Dextromethorphan
Quinidine
Quinidine gluconate